2-甲基-6-三氟甲基苯胺 | 88301-98-8

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-6-三氟甲基苯胺
• 中文别名: 2-甲基-6-(三氟甲基)苯胺；2-甲基6-三氟甲基苯胺
• 英文名称: 2-methyl-6-(trifluoromethyl)aniline
• CAS: 88301-98-8
• 化学式: C₈H₈F₃N
• mdl: MFCD03701069
• 分子量: 175.153
• InChiKey: LXPCTHRQJVSSIQ-UHFFFAOYSA-N

物化性质

• 沸点：
  198.8±35.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2921430090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  储存温度应保持在2-8°C，并避免光照。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methyl-6-(trifluoromethyl)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methyl-6-(trifluoromethyl)aniline
CAS number: 88301-98-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8F3N
Molecular weight: 175.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-6-三氟甲基苯胺 在 N-氯代丁二酰亚胺 、 溶剂黄146 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以52%的产率得到4-chloro-2-methyl-6-(trifluoromethyl)aniline
  参考文献：
  名称：

  [EN] SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME
  [FR] SULFONYLURÉES, COMPOSÉS APPARENTÉS, ET LEUR UTILISATION

  摘要：

  公开号：

  WO2016131098A8
• 作为产物：
  描述：

  邻氨基三氟甲苯 在 丁二酰亚胺 、 盐酸 、 sodium periodate 、 四磷十氧化物 、 palladium 10% on activated carbon 、 甲酸铵 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 16.0h， 生成 2-甲基-6-三氟甲基苯胺
  参考文献：
  名称：

  氟代利多卡因类似物作为局麻药的合成，坐骨神经阻滞活性评估和分子对接

  摘要：

  合成了三十种氟取代的利多卡因类似物（10a – e，11a – e，14a–e，15a–e，18a–e和19a–e），并将它们的坐骨神经阻滞活性评估为局部麻醉。大多数化合物显示出显着的效力，特别是化合物10a的效力比母体利多卡因大得多。包括10a在内的15种类似物的pKa值在7.5-7.8之间，适用于局部麻醉。化合物10a，14e通过分子对接研究，将利多卡因和利多卡因对接到局部麻醉药的三个靶受体中，以描绘结构与活性的关系并解释活性的差异。疏水相互作用和氢键被确定为分子结合的关键，这表明优化这些相互作用和/或利多卡因苯环上的三氟取代可以增强利多卡因类似物的局部麻醉性能。

  DOI：

  10.1007/s00044-019-02415-4

文献信息

• Phosphosulfonate herbicides
  申请人：Rohm and Haas Company

  公开号：US05500405A1

  公开（公告）日：1996-03-19

  This invention pertains to phosphosulfonates, having the general formula ##STR1## wherein Y is phenyl, naphthyl, benzyl, a (C.sub.5 -C.sub.8)cycloalkyl, a 5-membered heteroaromatic ring, a 6-membered heteraromatic ring, a fused 5,6-membered heteroaromatic ring, or a fused 6,6-membered heteroaromatic ring; and X is oxygen or sulfur; and R.sup.1 and R.sup.2 are each independently selected from substituted or unsubstituted alkyl, alkoxy, alkylthio, alkenyloxy, alkynyloxy, haloalkoxy, cyanoalkoxy, alkoxyalkoxy, cycloalkyloxy, cycloalkylalkoxy, alkylideneiminooxy, chloro, amino, phenyl or phenoxy; or R.sup.1 and R.sup.2 are both alkoxy, taken together with the phosphorus atom to form a 6-membered oxygen-containing ring; compositions containing these compounds and their use as herbicides.

  这项发明涉及磷磺酸酯，其一般公式为##STR1##其中Y为苯基、萘基、苄基、(C.sub.5 -C.sub.8)环烷基、5-成员杂芳环、6-成员杂芳环、融合的5,6-成员杂芳环或融合的6,6-成员杂芳环；X为氧或硫；R.sup.1和R.sup.2各自独立地选自取代或未取代的烷基、烷氧基、烷硫基、烯氧基、炔氧基、卤代烷氧基、氰基烷氧基、烷氧基烷氧基、环烷氧基、环烷基烷氧基、烷基亚胺氧基、氯、氨基、苯基或苯氧基；或R.sup.1和R.sup.2均为烷氧基，与磷原子一起形成一个6-成员含氧环；含有这些化合物的组合物及其用作除草剂。
• NEW COMPOUNDS
  申请人：HAUEL Norbert

  公开号：US20100240669A1

  公开（公告）日：2010-09-23

  The present invention relates to the compounds of general formula I wherein n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and X are defined as described hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the medicaments containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

  本发明涉及一般式I的化合物，其中n、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和X的定义如下所述，其对映体、非对映体、混合物及其盐，特别是其与有机或无机酸或碱形成的生理上可接受的盐，具有有价值的性质，其制备方法，含有药理学有效化合物的药物，其制备方法和用途。
• N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
  申请人：Griffith David A.

  公开号：US20120108619A1

  公开（公告）日：2012-05-03

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  这项发明提供了化合物的化学式(I)或其药用可接受的盐；其中G是R1，R2和R3如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、状况或紊乱中的使用。
• [EN] SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE MORPHOLINE ET DE THIOMORPHOLINE SUBSTITUÉS
  申请人：LUNDBECK & CO AS H

  公开号：WO2005087754A1

  公开（公告）日：2005-09-22

  The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

  本发明涉及一般式I的吗啉和硫代吗啉衍生物或其药用盐及其用途。
• [EN] ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS PHARMACEUTIQUES ARYLE, HÉTÉROARYLES ET HÉTÉROCYCLIQUES POUR LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2018160889A1

  公开（公告）日：2018-09-07

  Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

  提供了抑制补体因子D的抑制剂、药物组合物及其用途，以及它们的制备方法。所提供的化合物包括公式I、公式II、公式III、公式IV和公式V，或其药学上可接受的盐、前药、同位素类似物、N-氧化物或其分离异构体，可选地在药学上可接受的组合物中。本文描述的抑制剂针对因子D并抑制或调节补体级联反应。